HTSU.F Stock Overview
Manufactures and sells pharmaceuticals in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Hisamitsu Pharmaceutical Co., Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥24.56 |
| 52 Week High | JP¥36.00 |
| 52 Week Low | JP¥23.70 |
| Beta | 0.41 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -18.97% |
| 3 Year Change | n/a |
| 5 Year Change | -40.25% |
| Change since IPO | -9.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| HTSU.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -2.1% | -4.0% |
| 1Y | -19.0% | 9.1% | 24.0% |
Return vs Industry: HTSU.F underperformed the US Pharmaceuticals industry which returned 16.6% over the past year.
Return vs Market: HTSU.F underperformed the US Market which returned 19.4% over the past year.
Price Volatility
| HTSU.F volatility | |
|---|---|
| HTSU.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: HTSU.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HTSU.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1847 | 2,759 | Kazue Nakatomi | www.global.hisamitsu |
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders.
Hisamitsu Pharmaceutical Co., Inc. Fundamentals Summary
| HTSU.F fundamental statistics | |
|---|---|
| Market cap | US$1.91b |
| Earnings (TTM) | US$93.39m |
| Revenue (TTM) | US$923.31m |
20.4x
P/E Ratio2.1x
P/S RatioIs HTSU.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HTSU.F income statement (TTM) | |
|---|---|
| Revenue | JP¥145.42b |
| Cost of Revenue | JP¥64.36b |
| Gross Profit | JP¥81.06b |
| Other Expenses | JP¥66.35b |
| Earnings | JP¥14.71b |
Last Reported Earnings
May 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 200.54 |
| Gross Margin | 55.74% |
| Net Profit Margin | 10.11% |
| Debt/Equity Ratio | 0.4% |
How did HTSU.F perform over the long term?
See historical performance and comparisonDividends
2.1%
Current Dividend Yield44%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/07/20 14:49 |
| End of Day Share Price | 2024/04/23 00:00 |
| Earnings | 2024/05/31 |
| Annual Earnings | 2024/02/29 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hisamitsu Pharmaceutical Co., Inc. is covered by 14 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Toshiro Yoshinaga | Aizawa Securities Co. Ltd. |
| Ritsuo Watanabe | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Global Markets Japan Inc. |